Despite the fact that antithrombotic therapy (ATT) has little or even negative effects on the well-being of cancer patients during their last year of life, stopping ATT is rare in clinical practice. In contrast, antithrombotic therapy is often continued until death, resulting in excess bleeding, higher healthcare costs, and increased disease burden. SERENITY aims to develop an information-driven, palliative care shared decision-making process enabled by a user-friendly, easily accessible, web-based shared-decision support tool (SDST) that will facilitate treatment decisions regarding appropriate use of antithrombotic therapy in cancer patients at the end of life. SERENITY will use a comprehensive approach consisting of a combination of realist review, flash mob research, qualitative interviews, epidemiologic studies, and a randomized controlled trial. The sub-project described here uses the flashmob research approach to address healthcare professionals from various institutions, who deal with end-of-life care in cancer patients, or prescribe antithrombotic medication to cancer patients.The survey will be conducted with approx. 800 physicians from eight European countries, all represented in the SERENITY consortium.
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Current practice patterns across Europe with regard to the use of antithrombotic treatment in end-of-life care of cancer patients
Timeframe: 7 days
Relevance of patient's age for the decision on continuation or discontinuation of antithrombotic therapyin cancer patients during end-of-life care
Timeframe: 7 days
Relevance of patient's prognosis for the decision on continuation or discontinuation of antithrombotic therapyin cancer patients during end-of-life care
Timeframe: 7 days
Relevance of patient's performance status (Eastern Cooperative Oncology Group
Timeframe: 7 days
Relevance of patient's type of antithrombotic medication for the decision on continuation or discontinuation of antithrombotic therapy
Timeframe: 7 days
Relevance of patient's indication for antithrombotic medication for the decision on continuation or discontinuation of antithrombotic therapy
Timeframe: 7 days
Relevance of patient's thrombotic risk for the decision on continuation or discontinuation of antithrombotic therapy
Timeframe: 7 days
Relevance of patient's bleeding risk for the decision on continuation or discontinuation of antithrombotic therapy
Timeframe: 7 days
Relevance of patient's symptom burden for the decision on continuation or discontinuation of antithrombotic therapy
Timeframe: 7 days
Relevance of patient's medication burden for the decision on continuation or discontinuation of antithrombotic therapy
Timeframe: 7 days
Relevance of patient's preference (pro/contra continuation) for the decision on continuation or discontinuation of antithrombotic therapy
Timeframe: 7 days
Relevance of physician's experience (with deprescribing) for antithrombotic medication for the decision on continuation or discontinuation of antithrombotic therapy
Timeframe: 7 days